Looking Toward the Future of CLL Management
An expert hematologist/oncologist highlights key takeaways for the future management of chronic lymphocytic leukemia given an evolving therapeutic landscape.
Optimal Treatment Strategies for Chronic Lymphocytic Leukemia
Practical advice on optimal toxicity management and sequencing of therapy in patients with chronic lymphocytic leukemia.
Acalabrutinib vs Ibrutinib: Head-to-Head Data in Previously Treated CLL
Tara Graff, DO, MS, reflects on the head-to-head comparison data of acalabrutinib vs ibrutinib in patients with previously treated CLL.
Frontline BTKi Therapy in CLL: The ELEVATE-TN Study 4-Year Follow-up
Expert insight on the use of frontline BTK inhibitor monotherapy over combination therapy in CLL regarding the ELEVATE-TN trial’s readout.
Rationale and Use of BTK Inhibitors as Initial Treatment for CLL
A comprehensive breakdown of the rationale behind targeting BTK signaling in CLL, as well as considerations for clinical experience with the available BTK inhibitors.
The Evolution of CLL Treatment
Tara Graff, DO, MS, outlines the current treatment paradigm for chronic lymphocytic leukemia by discussing the use of novel agents, molecular testing, and risk stratification.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512